Targeting syndecan-1: new opportunities in cancer therapy
Abstract
Syndecan-1 (SDC1, CD138) is one of the heparan sulfate proteoglycans and is essential for maintaining normal cell morphology, interacting with the extracellular and intracellular protein repertoire, as well as mediating signaling transduction upon environmental stimuli. The critical role of SDC1 in promoting tumorigenesis and metastasis has been increasingly recognized in various cancer types, implying a promising potential of utilizing SDC1 as a novel target for cancer therapy. This review summarizes the current knowledge on SDC1 structure and functions, including its role in tumor biology. We also discuss the highlights and limitations of current SDC1-targeted therapies as well as the obstacles in developing new therapeutic methods, offering our perspective on the future directions to target SDC1 for cancer treatment.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jul 01, 2022
- Source ID
- 10.1152/ajpcell.00024.2022
Entities
People
- Haoqiang Ying
- Shuaitong Chen
- Wantong Yao
- Zecheng Yang
Organizations
- American Association for Cancer Research
- National Cancer Institute
- Pancreatic Cancer Action Network
- United States Department of Defense
- University of Texas at Austin